CH
抗体药类似物
Research Grade Tibulizumab
All
  • CatalogTD-HS856106
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBispecific, LY 3090106, LY-3090106, LY3090106, CAS: 1849636-24-3
  • Specification
    1mg
  • Prices
    ¥询价
Customized service consulting

Research Grade Tibulizumab


Catalog No. TD-HS856106
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype IgG4-kappa-[scFv]2
Expression system Mammalian Cells
Species Human
Clonality Monoclonal
Target CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Endotoxin level Please contact with the lab for this information.
Purity >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession Q16552 & Q9Y275
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate Names Bispecific, LY 3090106, LY-3090106, LY3090106, CAS: 1849636-24-3
Background Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.
Note For research use only. Not suitable for clinical or therapeutic use.